Skip to main content

Advertisement

SpringerLink
Log in

The long-term effects of lamivudine treatment in patients with HBeAg-negative liver cirrhosis

  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

In hepatitis B virus (HBV)-related liver cirrhosis, patients with HBV replication show a higher mortality rate than those without. We aimed to investigate the long-term effects of lamivudine on HBV DNA suppression, Child-Pugh score, and survival in patients with hepatitis Be antigen (HBeAg)-negative liver cirrhosis.

Methods

Sixty-eight patients (51 male, 17 female) diagnosed with HBV-positive liver cirrhosis, who were monitored by the hepatology and liver transplantation outpatient clinics of our hospital between June 1999 and May 2007, were included in the study. Lamivudine (100 mg/day) was administered orally. Follow-up visits were scheduled monthly during the first 3 months, and every 3 months thereafter. Complete blood count, haemostasis, biochemistry (aspartate aminotransferase [AST], alanine aminotransferase [ALT], amylase, urea, creatinine, total bilirubin, direct bilirubin, total protein, albumin), and alpha-foetoprotein were recorded every 3 months. HBV DNA levels, abdominal ultrasound and the Child-Pugh score were evaluated every 6 months.

Results

Sixty-eight patients (mean age, 52.05±12.6 years) were monitored for 49.51±18.51 months. Basal ALT, HBV DNA levels and Child-Pugh scores were 103.9±73.9 IU/ml, 4133±121,94 IU/ml, and 7.6±2.4, respectively. The ALT normalisation was 59.7% during the first year, 68.2% during the second year and 44.4% during the fifth year. There was a significant decrease in Child-Pugh scores in the first 3 follow-up years when compared with the baseline score (P<0.05). During the treatment, HBV DNA positivity and YMDD mutations were determined in 20 of 68 (29.4%) patients at 46±17.9 months. Nine patients (13.2%) developed hepatocellular carcinoma at 44.8±21.5 months. Thirteen patients (19.1%) died during the treatment due to liver failure or variceal bleeding.

Conclusion

Lamivudine is beneficial in patients with HBeAg-negative liver cirrhosis in terms of improvement in liver function and enhancement of survival and quality of life. An HBV DNA suppressive effect and improvement in Child-Pugh score were seen especially in the first years. It is important to be aware of YMDD mutation early, as addition of new antivirals is necessary to overcome unwanted results of the mutation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97–107.

    Article  PubMed  CAS  Google Scholar 

  2. de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology. 1992;103:1630–1635.

    PubMed  Google Scholar 

  3. Realdi G, Fattovich G, Hadziyannis S, et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol. 1994;21:656–666.

    Article  PubMed  CAS  Google Scholar 

  4. Liaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology. 1991;13:627–631.

    Article  PubMed  CAS  Google Scholar 

  5. Fontana RJ, Lok AS. Lamivudine treatment in patients with decompensated hepatitis B cirrhosis: for whom and when? J Hepatol. 2000;33:329–332.

    Article  PubMed  CAS  Google Scholar 

  6. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology. 2001;34:411–416.

    Article  PubMed  CAS  Google Scholar 

  7. Kapoor D, Guptan RC, Wakil SM, et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol. 2000;33:308–312.

    Article  PubMed  CAS  Google Scholar 

  8. Bolukbas C, Bolukbas FF, Kendir T, et al. The effectiveness of lamivudine treatment in cirrhotic patients with HBV precore mutations: a prospective, open-label study. Dig Dis Sci. 2006;51:1196–1202.

    Article  PubMed  CAS  Google Scholar 

  9. Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E. European Concerted Action on Viral Hepatitis (EUROHEP). Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol. 2002;97:2886–2895.

    Article  PubMed  Google Scholar 

  10. Perrillo R, Tamburro C, Regenstein F, et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology. 1995;109:908–916.

    Article  PubMed  CAS  Google Scholar 

  11. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999;341:1256–1263.

    Article  PubMed  CAS  Google Scholar 

  12. Nevens F, Main J, Honkoop P, et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology. 1997;113:1258–1263.

    Article  PubMed  CAS  Google Scholar 

  13. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut. 2000;46:562–568.

    Article  PubMed  CAS  Google Scholar 

  14. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during longterm lamivudine therapy. Gastroenterology. 2003;124:105–117.

    Article  PubMed  CAS  Google Scholar 

  15. Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology. 2000;31:207–210.

    Article  PubMed  CAS  Google Scholar 

  16. Perrillo RP, Wright T, Rakela J, et al. Lamivudine North American Transplant Group. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology. 2001;33:424–432.

    Article  PubMed  CAS  Google Scholar 

  17. Andreone P, Biselli M, Gramenzi A, et al. Efficacy of lamivudine therapy for advanced liver disease in patients with precore mutant hepatitis B virus infection awaiting liver transplantation. Transplantation. 2002;74:1119–1124.

    Article  PubMed  CAS  Google Scholar 

  18. Manolakopoulos S, Karatapanis S, Elefsiniotis J, et al. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. Am J Gastroenterol. 2004;99:57–63.

    Article  PubMed  CAS  Google Scholar 

  19. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646–649.

    Article  PubMed  CAS  Google Scholar 

  20. Karayalçin S, Yurdaydin C, Bozdayi AM, Bozkaya H. Is it possible to decrease at one year the lamivudine treatment induced serum HBV-DNA breakthrough rates? Gastroenterology. 2000;118(suppl):2348. Abstract.

    Google Scholar 

  21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481.

    Article  Google Scholar 

  22. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–1531.

    Article  PubMed  CAS  Google Scholar 

  23. Lok AS, McMahon BJ. Corrections to AASLD guidelines on chronic hepatitis B. Hepatology. 2007;45:1347.

    Article  Google Scholar 

  24. Fontana RJ, Keeffe EB, Carey W, et al. Hepatitis B Virus Orthotopic Liver Transplantation Study Group. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl. 2002;8:433–439.

    Article  PubMed  Google Scholar 

  25. Nikolaidis N, Vassiliadis T, Giouleme O, et al. Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-Hbe positive/HBeAg-negative chronic hepatitis B. Clin Transplant. 2005;19:321–326.

    Article  PubMed  Google Scholar 

  26. Ooga H, Suzuki F, Tsubota A, et al. Efficacy of lamivudine treatment in Japanese patients with hepatitis B virus-related cirrhosis. J Gastroenterol. 2004;39:1078–1084.

    Article  PubMed  CAS  Google Scholar 

  27. Hann HW, Fontana RJ, Wright T, et al. United States Lamivudine Compassionate Use Study Group. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl. 2003;9:49–56.

    Article  PubMed  Google Scholar 

  28. Moskovitz DN, Osiowy C, Giles E, Tomlinson G, Heathcote EJ. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance. J Viral Hepat. 2005;12:398–404.

    Article  PubMed  CAS  Google Scholar 

  29. Chu CM. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol. 2000;15(suppl E):25–30.

    Article  Google Scholar 

  30. Hui AY, Chan HL, Leung NW, Hung LC, Chan FK, Sung JJ. Survival and prognostic indicators in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation. J Clin Gastroenterol. 2002;34:569–572.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gastroenterology Department, Turkiye Yuksek Ihtisas Hospital, Suleymanbey Sok. 29/10, Maltepe, 06570, Ankara, Turkey

    Z. Mesut Yalin Kilic, Sedef Kuran, Meral Akdogan, Bahattin Cicek, Dilek Oguz, Bulent Odemis & Nurgul Sasmaz

Authors
  1. Z. Mesut Yalin Kilic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sedef Kuran
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Meral Akdogan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bahattin Cicek
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dilek Oguz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bulent Odemis
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nurgul Sasmaz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Z. Mesut Yalin Kilic.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kilic, Z.M.Y., Kuran, S., Akdogan, M. et al. The long-term effects of lamivudine treatment in patients with HBeAg-negative liver cirrhosis. Adv Therapy 25, 190–200 (2008). https://doi.org/10.1007/s12325-008-0038-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-008-0038-6

Keywords

Search

Navigation